Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma

Part of paid clinical trials in Duarte, California.

Sponsor
California Cancer Consortium
Study ID
NCT00022607
Phase
PHASE2
Status
Completed

Conditions

  • Multiple Myeloma and Plasma Cell Neoplasm

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Thalidomide may stop the growth of cancer cells by stopping blood flow to the tumor. It is not yet known whether bevacizumab works better with or without thalidomide for multiple myeloma. PURPOSE: This randomized phase II trial is to see if bevacizumab works better with or without thalidomide in treating patients who have relapsed or refractory multiple myeloma.

Key Dates

First listed
Jan 27, 2003
Start date
Jan 31, 2002
Status verified
Oct 2004
Completion
May 31, 2006

Study Design

Allocation
RANDOMIZED
Primary purpose
TREATMENT

Locations (4)

FacilityCityStateZIPSite coordinators
City of Hope Comprehensive Cancer CenterDuarteCalifornia91010-3000-
USC/Norris Comprehensive Cancer Center and HospitalLos AngelesCalifornia90089-
University of California Davis Cancer CenterSacramentoCalifornia95817-
University of Chicago Cancer Research CenterChicagoIllinois60637-1470-

Find similar trials in Duarte, CA

By research site
City of Hope Comprehensive Cancer Center· Duarte, CAUSC/Norris Comprehensive Cancer Center and Hospital· Los Angeles, CAUniversity of California Davis Cancer Center· Sacramento, CAUniversity of Chicago Cancer Research Center· Chicago, IL

Related Studies